News

Accentus Medical Advances Application of Agluna® for Cardiac Device Applications

19 May 2017

Accentus Medical, a leading developer of advanced surface modifications and coating technologies for implantable medical devices, is pleased to announce a funding award of £149,199 from Innovate UK, the UK’s innovation agency. The award is targeted towards a project focused on testing the safety and efficacy of Agluna® silver ion-based antimicrobial surface treatment applied to titanium casing of cardiac implantable electronic devices (CIEDs). A parallel work package within the project is targeting development and proof of concept testing of a biocompatible, anti-microbial surface on a novel cardiac device.
Implantation rates of CIEDs, including pacemakers, are rising with an expanding range of...

Read Full StoryDownload PDFShow SummaryHide Summary

Accentus Medical Wins OBN Best New UK Medtech Development Award

05 October 2015

Accentus Medical, a leading developer of advanced surface modifications and coating technologies, is delighted to announce its success in winning the
Best New UK Medtech Development Programme in the OBN 2015 Awards.

http://www.obn.org.uk/press-release/obn-annual-awards-2015-celebrates-uks-life-sciences-champions/

The winners in each of twelve award categories were announced at the OBN Annual Awards Dinner on Thursday 1 October 2015, held at the Ashmolean Museum, Oxford. The event was attended by senior executives and influential players from the most innovative...

Read Full StoryDownload PDFShow SummaryHide Summary

Accentus Medical Shortlisted for OBN UK Medtech Development Award

04 September 2015

Accentus Medical, a leading developer of advanced surface modifications and coating technologies, is pleased to announce it has been shortlisted as a top three finalist for the Best New UK Medtech Development Programme in the OBN 2015 Awards.

http://www.obn.org.uk/news/obn-annual-awards-2015-shortlisted-entrants-announced/

Accentus Medical’s shortlisting reflects a highly successful year, which has seen peer review publication of data evidencing clinical performance of its innovative Agluna® silver ion based antimicrobial surface technology through its commercial........

Read Full StoryDownload PDFShow SummaryHide Summary

Innovate UK Funding Award for Acusure Ag® Production Line Readiness

30 July 2015

Accentus Medical, a leading developer of advanced surface modifications and coating technologies, is pleased to announce a funding award of £70,736 from
Innovate UK, the UK’s innovation agency, towards a project targeted at demonstrating production line readiness of its innovative Acusure Ag® silver ion based antimicrobial hydroxyapatite coating for orthopaedic implants. This award has been received from Innovate UK’s Collaborative R&D competition for funding: Production line readiness for high-value manufacturing....

Read Full StoryDownload PDFShow SummaryHide Summary

Accentus Medical profiled in publication celebrating 750 years of parliament in Britain

30 June 2015

Accentus Medical, a leading developer of advanced surface modifications and coating technologies, is pleased to announce its association with the project marking 750 years of parliament in Britain. The project recently culminated in the publication of The Story of Parliament: Celebrating 750 years of parliament in Britain. The company is profiled within a section focused on the Department of Health, and its endeavours to increase the integration of health and social care, with long-term sustainability in mind. Accentus Medical is featured as an innovative technology firm whose products are helping to reduce....

Read Full StoryDownload PDFShow SummaryHide Summary

Professor Owen Addison Appointed to Accentus Medical Advisory Board

08 May 2015

Accentus Medical, a leading developer of advanced surface modifications and coating technologies, is pleased to announce the appointment of Professor Owen Addison to the company’s Advisory Board, as Advisor on Dental Implants.

Professor Addison holds a position as Chair in Applied Biomaterials, and Honorary Consultant in Restorative Dentistry, at University of Birmingham School of Dentistry, a leading UK dental school with global academic reputation. Having completed his PhD in Biomedical Material Science in 2007, and higher clinical specialist training in Restorative Dentistry in 2012, Professor Addison is one of a very small number of dentally qualified academics to hold a National Institute of Health Research (NIHR) Clinician Scientist award. In 2013, he was awarded the International Association of Dental Research / Academy of Osseointegration Innovation in Implants Sciences Award.

Dr James Shawcross, Director of Research & Development, said: “We are delighted that....

Read Full StoryDownload PDFShow SummaryHide Summary

Peer Review Publication of Agluna® Clinical Outcome Data

13 February 2015

Accentus Medical, a leading developer of advanced surface modifications and coating technologies, is pleased to report the publication in a leading peer review orthopaedic journal of the case-control study demonstrating significant infection rate reduction in high-risk patients receiving Agluna® treated custom limb salvage devices. The Agluna® technology is supplied by Accentus Medical under licence to Stanmore Implants on its custom (patient specific) limb salvage devices.

Published in February edition of The Bone & Joint Journal

http://www.bjj.boneandjoint.org.uk/content/97-B/2/252.abstract

the clinical paper reports a case-control study undertaken at the Royal Orthopaedic Hospital, Birmingham, in which 85 patients receiving Agluna® treated tumour implants

Read Full StoryDownload PDFShow SummaryHide Summary

Agluna® Set for Acceleration into the Dental Implant Sector

16 January 2015

Accentus Medical, a leading developer of advanced surface modifications and coating technologies, is pleased to have been awarded a Phase 1 grant from the European Commission’s Horizon 2020 SME Instrument, managed by EASME (the European Unions’ Executive Agency for Small and Medium Sized Enterprises).

The grant is awarded in support of Project ADA - Accelerating the Dissemination of Agluna®, a clinically proven innovative silver ion based anti-microbial surface technology, from the orthopaedic sector into the dental implant sector.

Agluna® has already demonstrated a significant reduction in...

Read Full StoryDownload PDFShow SummaryHide Summary

Accentus Cardiac to bring Agluna® Technology to the Cardiac Device Market

19 December 2014

Accentus Medical, a leading developer of advanced surface modifications and coating technologies, has announced today the launch of a new business venture Accentus Cardiac Limited to exploit its innovative Agluna® anti-microbial surface technology within the cardiac device market. Accentus Cardiac will exploit Agluna® in the global market via an intellectual property licence granted from Accentus Medical Limited.

The launch of this business venture in the cardiac device market builds upon the clinical success already achieved with Agluna® treated devices within the.....

Read Full StoryDownload PDFShow SummaryHide Summary

Accentus Medical Launches Agluna® Manufacturing Capability

06 November 2014

Accentus Medical is pleased to announce the launch of its manufacturing capability for commercial supply of Agluna® anti-microbial surface technology for titanium medical implants.
The launch is the culmination of a project building on successful design and development of pilot manufacturing capability during 2010/11 with financial catalyst support from InnovateUK (Technology Strategy Board) High Value Manufacturing grant. Subsequent to that prototype demonstration project, the company has completed detailed process development and validation studies in order to qualify the plant for customer manufacturing streams.

Read Full StoryDownload PDFShow SummaryHide Summary

Agluna® Treated Devices Significantly Reduce Infection Rates

21 October 2013

Oxford, 21 October 2013 … Accentus Medical is pleased to announce the results of a retrospective review of infection rates associated with orthopaedic limb salvage devices treated with its innovative Agluna® surface technology. Agluna® harnesses the anti-microbial properties of silver ions in preventing device related infection. The technology is supplied by Accentus Medical under licence to Stanmore Implants Worldwide on its custom patient specific limb salvage devices.

The clinical team at Royal Orthopaedic Hospital (ROH), Birmingham, UK, has conducted a study comparing the incidence of.........

Read Full StoryDownload PDFShow SummaryHide Summary

Accentus Medical Announces Completion of Management Buyout

23 September 2013

Oxford, 23 September 2013 … Accentus Medical, a global leader in silver-based anti-microbial implant surfaces, has announced today the successful completion of a management buyout. The buyout was delivered through a combination of investment from the incumbent management team, and a spectrum of private investors with knowledge and expertise in the implantable medical device market and advanced materials sector. The buyout transaction eliminates historic debt and provides the company with fresh equity investment to take forward the business plan.

Read Full StoryDownload PDFShow SummaryHide Summary

Accentus presents poster at 1st International PEEK Meeting, Philadelphia, PA, USA

01 May 2013

Accentus presented a poster, at The Union League, Philadelphia, PA, USA, on Thursday and Friday, April 25 and 26, 2013.
Paper:
Imparting osseo-integrating properties to the surface of PEEK implants with hydroxyapatite and titanium plasma
spray coating while maintaining the substrate material’s original chemical and physical properties

Read Full StoryDownload PDFShow SummaryHide Summary

Accentus Medical Strengthens Board of Directors to Support Growth Drive

04 February 2013

Oxford, 4 February 2013 … Accentus Medical, a global leader in silver-based anti-microbial implant surfaces, is pleased to announce the appointment of Brian Howlett and Laurie Rostron to its board of directors.

Read Full StoryDownload PDFShow SummaryHide Summary

Acusure® Technology gains further approval for use in the USA

21 January 2013

Oxford, 21 January 2013 ... Accentus Medical is pleased to announce that one of its customers, FHi, a member of the FH Orthopedics Group, a long established French manufacturer of orthopaedic implants, recently gained a 510(K) approval from the US Food and Drug Administration (FDA) for its Arrow Reverse Total Shoulder prosthesis. This product incorporates the proprietary Acusure® inert gas plasma spray coating, applied by Accentus Medical at our facility in Harwell. This is the latest product approval obtained by our customers for free sale of Acusure® coated products in the United States of America.

Read Full StoryDownload PDFShow SummaryHide Summary

Accentus Medical Appoints New Business Development Manager

01 September 2012

Oxford, 1 September 2012 … Accentus Medical, a global leader in silver-based anti-microbial implant surfaces, is pleased to announce the appointment of James Armstrong as Business Development Manager. James has over 10 years’ experience within the advanced coating technology industry and holds broad production and process knowledge. He has a track record of working within the high-growth SME sector, successfully achieving market traction and adoption of proprietary coating and other medical device technologies within multinational corporations, in the healthcare and other industry sectors.

Read Full StoryDownload PDFShow SummaryHide Summary

Accentus Medical innovation recognised at Oxfordshire Business Awards

21 June 2012

Accentus Medical has been recognised as a successful innovation company at the 2012 Oxfordshire Business Awards. Based at the Harwell Oxford campus, Accentus is a developer and FDA approved manufacturer focused on improving the clinical performance of medical implants.

Read Full StoryDownload PDFShow SummaryHide Summary

Accentus Medical anti-infective Agluna® technology awarded CE mark as component of Stanmore Implants METS tumour replacement system

05 January 2012

Accentus Medical, a leading UK medical technology company that develops and applies advanced coatings and surface treatments to a wide range of medical devices, announced today that the first medical device to incorporate its Agluna® silver anti-infective technology has received a European CE mark. The METS modular tumour replacement system manufactured by Stanmore Implants Worldwide is already a market leader in its field of massive tumour replacement and limb salvage devices. Following the award of the CE mark, the system will also be available with the Agluna® surface treatment option.

Read Full StoryDownload PDFShow SummaryHide Summary

Accentus Medical Set for Further Growth

09 November 2010

Accentus Medical, a leading UK medical technology company that supplies advanced coatings and surface treatments to the medical device industry, announced today that it has successfully completed the installation and initial demonstration of a prototype manufacturing plant for its Agluna® anti-infective technology, following the award of a grant worth £330,000 from the Technology Strategy Board within the High Value Manufacturing call.

Read Full StoryDownload PDFShow SummaryHide Summary

Accentus Medical to Exhibit at Venturefest 2010

23 June 2010

Accentus Medical, a leading medical technology company which provides advanced coatings and surface treatments for orthopaedic implants, will be exhibiting at VentureFest 2010.

Read Full StoryDownload PDFShow SummaryHide Summary

Accentus Medical Wins Best Medical Devices and Healthcare Award

04 November 2009

Accentus Medical, a leading medical technology company which provides advanced coatings and surface treatments for orthopaedic implants, has been named as the Winner of the Best Medical Devices and Healthcare Technologies Award at the Martin and Audrey Wood Enterprise Awards 2009.

Read Full StoryDownload PDFShow SummaryHide Summary

Accentus Medical Wins Major Technology Innovation Award

31 October 2008

Accentus Medical is proud to announce that it has been presented with a major award from the London Technology Fund, Londons specialist investor in new technology companies. At an Awards Ceremony in London on 29th October, the company was declared winner of the Life Sciences sector award, and also the overall Grand Prix.

Read Full StoryDownload PDFShow SummaryHide Summary

Events

No events currently scheduled.